Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of STI-1558 (Olgotrelvir) in Healthy and SARS-CoV-2 Positive Subjects
NCT05523739Phase 1Completed
- Sponsor
- ACEA Pharmaceuticals
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of olgotrelvir in coronavirus disease 2019 (COVID-19) (7 cohorts), sponsored by ACEA Pharmaceuticals. Primary endpoint: Adverse Events, laboratory tests, thyroid function, physical examination, vital signs at Day 29. Started Sep 2022; status: completed.
02
Drugs
olgotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05523739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05523739.